M. El-Naa, MonaF. El-Refaei, MohamedA. Nasif, WesamI. El-Brairy, Amany2020-01-232020-01-2320141- Hamelmann, E., Tadeda, K., Oshiba, A., Gelfand, E.W., 1999. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness - a murine model. Allergy, 54: 297-305. 2- Patouchas, D., Efremidis, G., Karkoulias, K., Zoumbos, N., Goumas, P., Spiropoulos, K., 2008. Lung function measurements in traditional bakers. Acta Biomed, 79(3):197-203. 3- Jaudszus, A., Krokowski, M., Möckel, P., Darcan, Y., Avagyan, A., Matricardi, P., et al., 2008. Cis-9, trans-11-conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPAR gamma-related mechanism in mice. J Nutr, 138: 1336-1342. 4- Walter, D.M, McIntire, J.J., Berry, G., McKenzie, A.N., Donaldson, D.D., DeKruyff, R.H., et al., 2001. Critical role for IL-13 in the development of allergeninduced airway hyperreactivity. J Immunol, 167: 4668–4675. 5- Geha, R.S., Jabara, H.H., Brodeur, S.R., 2003. The regulation of immunoglobulin E class-switch recombination.Nat Rev Immunol, 3: 721– 732. 6- Hamelmann, E., Wahn, U., Gelfand, E.W., 1999. Role of Th2 cytokines in the development of allergen-induced airway inflammation and hyperresponsiveness.Int Arch Allergy Immunol, 118: 90–1194. 7- Swain, S.L., Weinberg, A.D., English, M., Huston, G., 1990. IL-4 directs the development of TH2-like helper/effectors. J Immunol, 145: 3796–3806. 8- Hamelmann, E., and Gelfand, E.W., 2001. IL-5-induced airway eosinophilia– the key to asthma? Immunol Rev, 179: 182–191. 9- Jiang, C., Ting, A.T., Seed, B., 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature, 391: 82–86. 10- Sugiyama, H., Nonaka, T., Kishimoto, T., Komoriya, K., Tsuji, K., Nakahata, T., 2000. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol, 30(12): 3363-3370. 11- Reddy, R.C., Keshamouni, V.G., Jaigirdar, S.H., Zeng, X., Leff, T., Thannickal, V.J., 2004. Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-γ ligands. Am J Physiol Lung Cell Mol Physiol, 286(3): 613–619. 12- Wang, A.C., Dai, X., Luu, B., Conrad, D.J., 2001. Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation. Am J Respir Cell Mol Biol, 24(6): 688–693. 8 Mona et al., 2014 Biochemistry letters, 9(1) 2014, Pages: 1-13 13- Patel, H.J., Belvisi, M.G., BishopBailey, D., Yacoub, M.H., Mitchell, J.A., 2003. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol, 170(5): 2663-2669. 14- Villegas, I., Martín, A.R., Toma, W., de la Lastra, C.A., 2004. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemiareperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol, 28: 195-203. 15- Mehta, J.L., Hu, B., Chen, J., Li, D., 2003. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol, 23: 2203-2208. 16- Piper, P.J., and Vane, J.R., 1969. Release of additional factors in anaphylaxis and its antagonism by antiinflammatory drugs. Nature, 223: 29-35. 17- Tavernier, J., Devos, R., Van der Heyden, J., Hauquier, G., Bauden, R., Fache, I., 1989. Expression of human and murine interleukin-5 in eukaryotic systems. DNA, 8(7): 491-501. 18- Crowther, J.R., 1995. ELISA. Theory and practice.Methods Mol Biol, 42:1-218. 19- Niskikimi, M., Roa, N.A., Yagi, K., 1972. The occurrence of superoxide anion in the reaction of reduced phenazinemethosulfate and molecular oxygen.Biophys Res Commun, 46:849- 854. 20- Clairborne, A., 1985. Catalase activity. In: Greenwald RA, ed. Handbook of methods for oxygen radical research. Boca Raton, FL: CRC Press Inc: 283-284. 21- Prins, G.K., and Loose, J.A., 1969. Glutathione.In Biochemical methods in red cell genetics.Volume Chapter 4.Academic press N. Y. D. London 126- 129. 22- Mauad, T., and Dolhnikoff, M., 2008. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med, 14(1):31-8. 23- Lambrecht, B.N., Hammad, H., 2013. Asthma: The importance of dysregulated barrier immunity. Eur J Immunol Oct 28.doi: 10.1002/eji.201343730 24- Honda, K., Marquillies, P., Capron, M., Dombrowicz, D., 2004. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol, 113: 882-888. 25- Lee, K.S., Park, S.J., Hwang, P.H., Yi, H.K., Song, C.H., Chai, O.H., et al., 2005. PPAR-gamma modulates allergic inflammation through upregulation of PTEN. FASEB J, 19: 1033-1035. 26- Ueki, S., Usami, A., Oyamada, H., Saito, N., Chiba, T., Mahemuti, G., et al., 2006. Procaterolupregulates peroxisome proliferator-activated receptor-γ expression in human eosinophils.Int Arch Allergy Immunol, 140: 35-41. 27- Miyazaki, Y., Tachibana, H., Yamada, K., 2002. Inhibitory effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of IgE heavy chain germline transcripts in the human B cell line DND39.BiochemBiophys Res Commun, 295(2):547-552. 28- Jo, S.H., Yang, C., Miao, Q., Marzec, M., Wasik, M.A., Lu, P., et al., 2006. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. J Immunol, 177(6): 3737-3745. 29- Rühl, R., Dahten, A., Schweigert, F.J., Herz, U., Worm, M., 2002. Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands. J Invest Dermatol 121(4):757-764. 30- Kim, S.R., Lee, K.S., Park, H.S., Park, S.J., Min, K.H., Jin, S.M., et al., 9 Mona et al., 2014 Biochemistry letters, 9(1) 2014, Pages: 1-13 2005. Involvement of IL-10 in peroxisome proliferator-activated receptor gammamediated anti-inflammatory response in asthma. Mol Pharmacol, 68(6): 1568- 1575. 31- Woerly, G., Honda, K., Loyens, M., Papin, J.P., Auwerx, J., Staels, B., et al., 2003. Peroxisome proliferatoractivated receptors α and γ down-regulate allergic inflammation and eosinophil activation. J Exp. Med, 198: 411-421. 32- Kaleli, S., Akkaya, A., Akdogan, M., Gültekin, F., 2006. The effects of different treatments on prolidase and antioxidant enzyme activities in patients with bronchial asthma. Environ Toxicol Pharmacol, 22 (1): 35-39. 33- Van der Kuy, A., 1992. Future developments in the pharmacotherapy of lung disease. Pharm Week bl., 14: 221-223. 34- Majithiya, J.B., Paramar, A.N., Balaraman, R., 2005. Pioglitazone, a PPAR gamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res, 66(1): 150-161. 35- Ozbek, E., Ilbey, Y.O., Simsek, A., Cekmen, M., Mete, F., Somay, A., 2009. Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats. IntUrolNephrol Sep 25. [Epub ahead of print]. 36- Wood, L.G., Fitzgerald, D.A., Gibson, P.G., Cooper, D.M., Garg, M.L., 2000. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids, 35(9): 967-974. 37- Kanazawa, H., Kurihara, N., Hirata, K., Takeda, T., 1991. The role of free radicals in airway obstruction in asthmatic patients. Chest, 100: 1319-1322. 38- Daynes, R.A., and Jones, D.C., 2002. Emerging roles of PPARs in inflammation and immunity.Nat Rev Immunol, 2: 748-759. 39- Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Koenig, W., Hombach, V., et al., 2002. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implication for atherosclerosis and transplantationassociated arteriosclerosis. Circ. Res, 90:703-710. 40- Birrel, M.A., Patel, H.J., McCluskie, K., Wong, S., Leonard, T., Yacoub, M.H., et al., 2004. PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur. Respir J, 24 :18– 23. 41- Cuzzocrea, S., Mazzon, E., Dugo, L., Patel, N.S., Serraino, I., Di Paola, R., et al., 2003. Reduction in the evolution of murine type II collagen induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum, 48(12): 3544-3556. 42- Ito, H., Nakano, A., 2003. Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest, 83 (12): 1715- 1721.https://doi.org/https://t.ly/RK0GWMSA Google ScholarObjectives: To investigate the effects of a peroxisome proliferatoractivated receptor-gamma (PPAR-γ) agonist, rosiglitazone, on induced bronchial asthma in a murine model. Material and methods: Adult male guinea pigs were administered ovalbumin 100 mg/kg S.C. and 100 mg/kg I.P. Treatment with rosiglitazone (5 mg/kg/day, PO) was assessed for 21 days. On day 21, the animals were challenged with the same dose of ovalbumin and the ratio of FEV1 (forced expiratory volume in one second) to FVC (forced vital capacity), FEV1/ FVC, was measured using a spirometer. In addition, serum levels of interleukin-5 (IL-5) and immunoglobulin E (IgE) were assessed. The activities of superoxide dismutase (SOD) and catalase and the level of reduced glutathione (GSH) were determined in lung tissue homogenates. Furthermore, histopathological examination of the lung was performed. Results: treatment with rosiglitazone resulted in a profound improvement in lung function and histopathological features. These improvements were accompanied by a significant decrease in the serum levels of IL-5 and IgE. Moreover, the activities of antioxidant enzymes, including SOD and catalase, and the GSH level were significantly increased in the lung tissues of treated animals compared to those of untreated asthmatic animals. Conclusion: PPAR-γ agonist rosiglitazone may have potential in the development of therapies for bronchial asthmaenUniversity of Olive oil, Sucrose, Lipid peroxidation, Antioxidant enzymes, TestosteroneArticlehttps://doi.org/